Q1 2015 13F Holders as of 3/31/2015
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
196
-
Total 13F shares, excl. options
-
29.1M
-
Shares change
-
+1.97M
-
Total reported value, excl. options
-
$6.87B
-
Value change
-
+$478M
-
Put/Call ratio
-
0.9
-
Number of buys
-
112
-
Number of sells
-
-76
-
Price
-
$236.11
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q1 2015
231 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q1 2015.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 196 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29.1M shares
of 49.6M outstanding shares and own 58.67% of the company stock.
Largest 10 shareholders include ADAGE CAPITAL PARTNERS GP LLC (5.69M shares), FMR LLC (4.03M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3M shares), Capital Research Global Investors (2.04M shares), VANGUARD GROUP INC (1.66M shares), FRANKLIN RESOURCES INC (1.07M shares), BlackRock Fund Advisors (650K shares), WELLINGTON MANAGEMENT GROUP LLP (586K shares), BlackRock Institutional Trust Company, N.A. (569K shares), and JANUS CAPITAL MANAGEMENT LLC (549K shares).
This table shows the top 196 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.